MedicalCV to invest fresh funds in ablation system:
This article was originally published in Clinica
MedicalCV, of Minneapolis, Minnesota, has raised $13.6m through the sale of convertible preference stock and common stock warrants. It has also converted $4.4m of debt into such securities. The company says it the proceeds will fund further development of its Atrilaze surgical ablation system, and repay about $0.5m worth of convertible notes.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.